Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08OJF
|
||||
| Former ID |
DCL000130
|
||||
| Drug Name |
ICA-105665
|
||||
| Indication | Epilepsy [ICD10:G40] | Phase 2 | [1] | ||
| Company |
Icagen
|
||||
| Target and Pathway | |||||
| Target(s) | Potassium voltage-gated channel subfamily KQT member 3 | Target Info | Activator | [2] | |
| KEGG Pathway | Cholinergic synapse | ||||
| Reactome | Voltage gated Potassium channels | ||||
| Interaction between L1 and Ankyrins | |||||
| WikiPathways | Potassium Channels | ||||
| L1CAM interactions | |||||
| References | |||||
| REF 1 | Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy. Epilepsia. 2013 Aug;54(8):1437-43. | ||||
| REF 2 | New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.